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1.0 INTRODUCTION:  
The optimization of formulation is the backbone for any 
robust formulation. Formulation of an effective rapid 
dispersible tablet with ideal wetting and dispersion 
properties is required to achieve the rapid release profile of 
finished product. In preliminary work, the initial 
formulation was established to enhance the solubility and 
rapid release of Tolfenamic acid, but the optimization of 
size of granules and quantity of disintegrants was not the 
aim of experiment.1 As per the British pharmacopoeia, 
uniformity of dispersion and fineness of dispersion is the 
basic requirement of Orodispersible tablets.2 Delay in 
dispersion times, variation in dispersion, poor wetting 
tendency of formulation is some of the measurable factors 
showing insufficient optimization in formulation  of rapid 
dispersible tablets.3 
Granule size has an important role in compression and 
physical properties particularly disintegration and 
dispersion properties of tablets. Many workers have 
investigated the effect of granule size on disintegration and 
dispersion properties, Kassem et. al, 1972 using a lactose / 
starch / sodium alginate granulation found that as granule 
size decreased, the disintegration time increased and the 
coefficient of variation for disintegration time decreased.4 
Femi-Oyewo & Adefesco (1993) studied the variation in 
drug content uniformity of tablets with granule size. The 
paracetamol content increased as the granule size 
decreased to the 710-500 µm size fraction, attributed to 
increased granule flow-rate and tablet weight. Further 
reductions in size produced lower drug contents, but with 
fluctuations. 5 
Leonard (1971) studied the influence of granule size on the 
disintegration time of wet granulated sulphadiazine: maize 
starch formulations. Three size fractions (1200-1000µm, 
850-710 µm, 500-355 µm) were compared and individual 
tablets were externally lubricated to reduce the effect of 
magnesium Stearate. 6 
The size of granules plays a major role in disintegration 
and dispersion of rapid dispersible tablets. Still there is 
very limited work observed towards optimization of size of 
granules using various classes of disintegrants. The effect 
of granule size is dependent on the particular system and 
there is little work using super disintegrants. The present 
work studies effect of various size fractions of granules to 
determine the influence of disintegrant type and 
optimization of dispersion.  
2.0 MATERIALS: 
Tolfenamic Acid was a gift sample from Elder 
Pharmaceuticals Ltd, Navi Mumbai, India. Aspartame and 
Flavor Vanilla was a gift sample from Cadila 
Pharmaceuticals Limited, Ahmadabad, India. 
Microcrystalline cellulose, Sodium Lauryl sulfate, 
Povidone, Mannitol, Explotab, Ac di sol, Kyron T-314 and 
Kollidon CL were obtained from commercial sources. 
3.0 METHOD OF MANUFACTURING: 
3.1 SOLUBILITY ENHANCEMENT OF 
TOLFENAMIC ACID: 
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3.1.1 Co-micronization of Tolfenamic Acid for 
Solubility 
7 
The co-micronization of Tolfenamic Acid and diluents as 
per the given details of formulation in Table -1 was done 
by using Air-jet mill (Shree Engineering). Total three cycle 
of micronization was completed to insure the proper 
particle size reduction of blend.  
3.1.2 Physical evaluation of Co-micronization blend
 8 
The evaluation of micronized mixtures of Formulation A-1 
to A-4 was confirmed for particle size of TA mixture. The 
particle size was evaluated by using Malvern Mastersizer 
2000. The average particle size which was the mean 
particle size of 90% (d-0.9) of particle in sample was 
recorded for evaluation. 
3.2 MANUFACTURING OF BULK GRANULES:
 9 
Co-micronized blend of Tolfenamic acid was mixed in 
rapid mixer granulator (HSMG-10, Kevin Machinery) with 
slow impeller speed (75 RPM) for 10 minutes, PVP K-30 
was dissolved in distilled water to give a binder 
concentration of 6.0 % w/v. To granulate, the binder was 
added slowly over five minutes through a glass funnel to 
control the flow rate. The resultant material was wet 
massed through the required sieve. Granules were vacuum 
dried using vacuum dryer (Shree Engineering) at 55°C for 
150 – 180 minutes. The residual granule moisture content 
was determined by loss on drying. Granules were stored in 
double polythene bags until use to prevent moisture loss / 
gain.  
3.2.1 Separation of the Bulk Granules into different 
size fractions
 10 
Different granule size fractions were obtained by sifting of 
granules using mechanical shifter. The respective size 
fraction of granules such as #20 mesh passing and #40 
mesh retains  were collected by passing the bulk granules 
on higher sieve size (#20 mesh)  and retaining the granules 
on lower sieve size (#40 mesh). The same procedure was 
adopted in collection of remaining granules size fraction. 
The details of granules fraction with different disintegrants 
were summarized in Table – 2.0. 
 
Table 1: Formulation details Tolfenamic Acid Rapid Dispersible Tablets 
Ingredients /  
Formulation Code 
Explotab Ac-di-sol Kollidon-CL Kyron T-314 
BG-1 BG-2 BG-3 BG-4 
Co-micronization of Tolfenamic Acid 
Tolfenamic Acid 100.00 100.00 100.00 100.00 
Microcrystalline Cellulose 80.000 80.000 80.000 80.000 
Sodium Lauryl Sulfate 1.250 1.250 1.250 1.250 
Granulation Stage 
Explotab 5.000 -- -- -- 
Ac-di-sol -- 5.000 -- -- 
Kollidon-CL -- -- 5.000 -- 
Kyron T-314 -- -- -- 5.000 
Povidone (PVP K-30)  2.500 2.500 2.500 2.500 
Purified Water QS QS QS QS 
Mannitol 50.000 50.000 50.000 50.000 
Magnesium Stearate 1.250 1.250 1.250 1.250 
Tablet Weight in mg 240.00 240.00 240.00 240.00 
 
3.3 MANUFACTURING OF TABLETS:
 9 
The compression of granules was completed by using Cadmach single rotary compression machine. 9.00 mm FFBE 
chrome plated punching tools was used to avoid any sticking problem during compression. The average turret speed during 
compression was also kept in range of 10 – 12 RPM.  
Table 2: Separation of Bulk Granules in different size Granule Fractions (GF) 
Description /  
Formulation Code 
Explotab Ac-di-sol Kollidon-CL Kyron T-314 
BG-1 BG-2 BG-3 BG-4 
AGF = 1400 – 1000 µm 
#14/#18 
AGF-1 AGF-2 AGF-3 AGF-4 
BGF = 1000 – 710 µm 
#18/ #25 
BGF-1 BGF-2 BGF-3 BGF-4 
CGF = 710 – 500 µm 
#25/ #35 
CGF-1 CGF-2 CGF-3 CGF-4 
DGF = 500 – 250 µm 
#35/ #60 
DGF-1 DGF-2 DGF-3 DGF-4 
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3.4 PHYSICAL EVALUATION OF GRANULES: 
3.4.1 Loss on drying
 [10] 
Loss on drying is the loss of weight expressed as 
percentage w/w resulting from water and volatile matter 
of any kind that could be driven off under specified 
conditions. The loss on drying was calculated by using 
equation,  
% 𝐿𝑂𝐷 =
Weight of solvent in sample
Total weight of initial sample
X100 
 
Approximately 2.0 gms of dried granules were placed on 
aluminum disk of IR moisture balance. The loss on 
drying was recorded at 1050C for 10 minutes of time 
interval.  
3.4.2 Tapped and Untapped Density
 [10, 11] 
Un-tapped and tapped density was determined by placing 
a graduated cylinder containing a known mass of drug on 
a mechanical tapper apparatus which was operated for 
fixed number of taps (~ 100) until a powder bed volume 
had reached the minimum. The ratio of mass (weight) to 
volume is known as the untapped bulk density of 
material. The bulk density of a powder depends on 
particle size distribution. The equation for determining 
the bulk density and tapped density is, 
 
ρb =
M
Vp
 
  
ρt =
M
Vt
 
Where, „ρb‟ is untapped bulk density, „ρt‟  is tapped 
density , „M‟ is weight of sample in grams, „Vp‟ i s  final 
volumes of powder in cm3, „Vt‟ is tapped volume of 
powder in cm3. 
3.4.3 Angle of Repose
 [10, 11] 
Angle of repose of samples were measured by employing 
fixed height method, the specific amount of sample was 
poured through the funnel from the height of 2cm. The 
diameter of pile formed was measured and angle of 
repose was calculated by using following formula, 
θ =
h
r
 
 
Where, „θ‟ is angle of repose, „h‟ is height, and „r‟ is 
radius. The flow properties of granules were than 
interoperated by using table as shown in Table – 3. 
 
Table 3: Interpretation of angle of repose for Flow 
Properties 
Flow Properties Angle of Repose 
Excellent 25-30 
Good 31-35 
Fair-aid not needed 36-40 
Passable-may hang up 41-45 
Poor-must agitate, vibrate 46-55 
Very poor 56-65 
 
3.5 PHYSICAL EVALUATION OF TABLETS: 
3.5.1 Appearance 
Appearance of tablets was evaluated by taking twenty 
tablets of each formulation and visually checked for any 
discoloration or surface roughness on the core surface of 
tablet formulation. 
3.5.2 Weight Variation of tablets 
[11, 12] 
Weight variation of tablets was calculated by weighing 20 
tablets individually and determining the average weight. 
Tablet meets the test if not more than two of the 
individual weights deviate from percentage limits of 
7.5%.[12]   
3.5.3 Hardness
 [11, 13]  
The hardness of six tablets was determined using the 
Erweka type hardness tester and the average values were 
calculated for each formulation trials. 
3.5.4 Thickness
 [13]  
The Thickness of the tablets was determined by using 
Digital vernier calipers (Mitutoyo, Japan). Six tablets 
were used, and average values were calculated for each 
formulation trials. 
3.5.5 Friability
 [11] 
It was intended to determine the loss of mass under 
defined conditions. The friability of uncoated tablets was 
determined by using Electro lab Friability Apparatus. The 
20 pre weighed tablets were paced in friability apparatus 
and tested for the effects of abrasion and shock by 
utilizing a plastic chamber that revolves at 25 rpm 
dropping the tablets at a distance of six inches with each 
operation for 100 revolutions. The tablets are then de 
dusted and reweighed. The percentage for friability than 
calculated using following formula, 
 
𝐹𝑟𝑖𝑎𝑏𝑖𝑙𝑖𝑡𝑦  % 
=
Initial weight of Tablets− Final weight of Tablets
Initial weight of Tablets
X100 
 
As per the Indian pharmacopoeia the limit for friability 
tablets should not be more than 1% w/w.17 The  values  
for  both  Hardness  &  Friability  can  together  indicate  
the  mechanical strength of tablet.14  
3.5.6 Disintegration Time
 [13, 15] 
Disintegration is defined as time required by tablet to 
completely disintegrate and disappear from the basket. 
Disintegration time of tablets was evaluated as per the 
specification of disintegration time of dispersible and 
Orodispersible tablets in British pharmacopoeia.2 
Disintegration was carried out by using 600ml of 
disintegration media mentioning the temperature at 150C 
– 250C in disintegration basket. Disintegration discs were 
not used during disintegration. The use of discs during 
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disintegration reduces discrimination between good and 
bad formulations since the palpable residue on the mesh 
would not pass through without applying pressure and 
thus violating the principle of fluid penetration and 
particle separation.  
3.5.7 In vitro dispersion Time and Fineness of 
Dispersion
 [2, 16] 
Fineness of dispersion is specified in the specification of 
dispersible tablets. This taste is required to check the 
fineness and smoothness of dispersion of tablets. The 
same concepts were applied to correlate the dispersion of 
tablets in vivo by using pH 6.8 phosphate buffer. The in 
vitro dispersion time was observed by placing one tablet 
in a beaker containing 50 ml of pH 6.8 phosphate buffer 
at 370C + 10C, the time required to disperse the tablets 
was determined.[17] The same dispersion was passed 
through a sieve screen with a nominal mesh aperture of 
710 mm to confirm the fineness of dispersion. 
3.6 ANALYTICAL EVALUATION OF TABLETS: 
3.6.1 Assay of drug content in Tablets
 [2, 16]  
The analysis for drug content of formulation was 
developed based on monograph of Tolfenamic acid in 
British pharmacopoeia. 
Standard Preparation 
Weigh accurately & transfer about 150 mg of Tolfenamic 
acid in 100 ml   volumetric flask, dissolve it in 50ml of 
0.1 M NaOH & dilute up to mark with 0.1 M NaOH. 
Dilute 1 ml of the solution to 100 with 0.1 M NaOH.  
Sample Preparation  
The assay of each formulation was evaluated by taking 
twenty tablets and crushing the tablets by using Petri dish. 
240 mg equivalent weight of powdered Tolfenamic acid 
was taken in to a 100 ml volumetric flask. Add 80 ml of 
0.1 M NaOH. Shake for 30 minutes, dilute to 100 ml with 
0.1 M NaOH. Filter, discarding the first few ml of the 
filtrate and dilute 1 ml of this solution to 100 ml with 0.1 
M NaOH. Measure the absorbance of sample and 
standard preparation at 289 nm using 0.1 M NaOH as the 
blank with UV Spectrophotometer (Shimadzu). Calculate 
content of Tolfenamic acid per tablets, by following 
formula;  
% 𝑑𝑟𝑢𝑔 𝑐𝑜𝑛𝑡𝑒𝑛𝑡
=
Test Absorbance X Standard Concentration
standard Absorbance X weight of SD taken
 X dilution factor X 100 
3.6.2 In-vitro drug release kinetics
 2, 16 
In-vitro dissolution studies of all formulation were 
evaluated for the release profile of formulation. The basic 
objective of formulation was to develop the rapid 
disintegrating formulations, so release profile at various 
time intervals such as 5, 10, 15, 30, 45, and 60 minutes 
were analyzed for the evaluation of release kinetics.   
USP dissolution apparatus : Type-II Paddle, 100 
RPM 
Dissolution Medium  : 1000 ml, 
Phosphate Buffer pH 7.2  
Temperature   : 37 ± 0.5 0C 
Sampling Times (minutes) : 5, 10, 15, 30, 45, and 
60 
Preparation of Dissolution Medium 
Take 250 ml of ethanol 96 % and dilute to 1000 ml with 
Phosphate Buffer pH 7.2. 
Preparation of Phosphate Buffer pH 7.2 
Dissolve 40.8 g of Potassium dihydrogen phosphate in 
1500 ml of distilled water and adjust pH to 7.2 with 40% 
NaOH and then dilute to 4500 ml with water.  
Preparation of Standard solution 
Weigh accurately & transfer about 100mg of Tolfenamic 
acid in a 500 ml volumetric flask. Dissolve in 250ml 0.1M 
NaOH & dilute up to mark with 0.1 M NaOH. Dilute 1ml 
of resulting solution to 25 ml with 0.1M NaOH. 
Dissolution Procedure  
Dissolution of tablets was initiated by placing one tablet in 
each of six vessels containing 1000 ml dissolution 
medium, using paddle apparatus at 100 rpm for 60 
minutes. 5 ml of the sample solution was withdrawn from 
the dissolution beaker as per the given time interval and 
replacing the same volume by addition of dissolution 
media. The absorbance of sample solution and standard 
solution was measured by using UV Spectrophotometer 
(Shimadzu) at the maximum about 289 nm using 0.1M 
NaOH as blank. 
3.7 RESULT AND DISCUSSION: 
3.7.1 Physical Evaluation of Granules 
A – Loss on Drying 
Loss on drying of lubricated blend of various size 
fractions were tabulated in Table – 4. Lubricated blend 
with similar size fraction such as AGF1, AGF2, AGF3, 
and AFG4 had very similar residual moisture contents. 
The loss of drying of smaller granule size fractions tended 
to be higher than for the larger fractions, this may be due 
to the greater surface area for moisture loss occurring 
during fractionation. This highlights a potential problem 
in fractionating granulations. Although loss was not 
major in this case, the effect may be more pronounced in 
formulations of active with greater hygroscopicity.
 
Table 4: Effect of Granules size fraction on loss on drying (n=3) 
Form. Code/ 
LOD (%w/w) 
Explotab Ac-di-sol Kollidon-CL Kyron T-314 
1 2 3 4 
AGF 1.50 ± 0.22 1.45 ± 0.26 1.58 ± 0.26 1.40 ± 0.15 
BGF 1.65 ± 0.15 1.60 ± 0.19 1.69 ± 0.26 1.62 ± 0.22 
CGF 1.72 ± 0.15 1.79 ± 0.35 1.74 ± 0.19 1.68 ± 0.16 
DGF 1.80 ± 0.06 1.88 ± 0.10 1.82 ± 0.09 1.92 ± 0.12 
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B – Flow Properties of Granules 
Untapped density, tapped density, compressibility index, Hausner ratio and angle of repose of each size fraction were 
tabulated in Table - 5.  
Table 5: Physical properties of granules (n=3) 
Evaluation Parameter/ 
Formulation Code 
Explotab Ac-di-sol Kollidon-CL Kyron - T314 
1 2 3 4 
Bulk density 
(gm/ml) 
AGF 0.40 ± 0.01 0.42 ± 0.02 0.38 ± 0.01 0.36 ± 0.01 
BGF 0.43 ± 0.01 0.42 ± 0.02 0.42 ± 0.01 0.42 ± 0.01 
CGF 0.48 ± 0.01 0.45 ± 0.02 0.44 ± 0.01 0.47 ± 0.01 
DGF 0.52 ± 0.01 0.49 ± 0.01 0.53 ± 0.01 0.55 ± 0.01 
Tapped 
density 
(gm/ml) 
AGF 0.60 ± 0.02 0.58 ± 0.02 0.62 ± 0.02 0.64 ± 0.02 
BGF 0.65 ± 0.02 0.62 ± 0.01 0.65 ± 0.03 0.67 ± 0.01 
CGF 0.70 ± 0.02 0.68 ± 0.02 0.62 ± 0.02 0.69 ± 0.03 
DGF 0.79 ± 0.03 0.82 ± 0.01 0.75 ± 0.02 0.86 ± 0.02 
Angle of 
Repose 
AGF Fair to pass Good Poor Very Poor 
BGF Good Good Fair to pass Excellent 
CGF Excellent Excellent Good Good 
DGF Fair to pass Fair to pass Poor Fair to pass 
 
Density of granules with different size fraction changes as 
per the change in the size of granules. The granules with 
coarser or larger particle size such as 14/18; 1400 – 1000 
µm showing less density as compare to granules with less 
particle size such as 35/60; 500 – 250 µm. This may be 
due to less void space in granules with less particle size.  
Lubricated blend with similar size fraction such as AGF1, 
AGF2, AGF3, and AFG4 had very similar flow properties. 
But significant changes observed with change in size 
fraction of granules. Granules with smaller size fraction 
(35/60; 500 – 250 µm) and larger size fraction (14/18; 
1400 – 1000 µm) showing poor flow properties as 
compare to granules size fraction between 500 and 1000 
µm (18/25; 1000 – 710 µm & 25/35; 710 – 500 µm). 
On the basis of physical evaluation of granules with 
various size fractions it was clearly observed the impact of 
particle size of granules on the various physical parameters 
such as density and flow properties of granules.   
3.7.2 Physical Evaluation of Tablets 
The various physical evaluations for tablets with various 
size fraction of formulation were summarized in Table - 6. 
A - Appearance of Tablets 
The appearance of tablets found good without any 
significant defects for all formulations.  
B - Weight Variation of Tablets 
All weights falls within the range 240mg ± 7.5% . 
Lubricated blend with similar size fraction such as AGF1, 
AGF2, AGF3, and AFG4 had similar variation in weight. 
There were significant changes observed with change in 
size fraction of granules. Granules with smaller size 
fraction (35/60; 500 – 250 µm) showing higher side of 
variation during compression stage, this was probably due 
to poor flow properties of granules. Compression with 
medium size fraction of granules (25/35; 710 – 500 µm) 
showing less weight variation as compare to granules size 
fraction between 1000 and 1400 µm (14/18; 1400 – 
1000µm). This was basically due to change in particle size 
and flow properties of granules during compression stage.   
In agreement with others (Kassem et aI, 1972; Femi-
Oyewo & Adefeso, 1993), weight variation decreased as 
the granule size decreased due to better die fill and closer, 
more uniform packing.[4, 5] Tablet weight did not increase 
with granule size because die fill was adjusted for each 
granule fraction to give the correct mean tablet weight. 
This was necessary to avoid increases in tablet crushing 
strength resulting from greater tablet weights which would 
complicate the interpretation of results. 
C - Tablet Thickness and Hardness 
The thickness of tablets with different size fraction was 
compressed at fixed thickness range to avoid any variation 
during compression stage. For all formulations and granule 
size fractions, tablet hardness / crushing strength increased 
with reducing the particle size fraction of granules. 
Disintegration time and tablet crushing strength may be 
directly related. [5] The increased inter particulate bonding 
makes particle separation in the deaggregation process 
more difficult.  At the same compression force, granule 
size fractions containing intra-granular Explotab and Ac-
Di-Sol tend to produce tablets of slightly higher crushing 
strengths than those Containing Kollidon-CL and Kyron 
K-314. 
D - Tablets Friability  
Resistance to abrasion or friability is an important 
consumer attribute. It indicates how the tablet will 
withstand the tumbling effect encountered during 
manufacture, packaging, transport and handling. There is 
no clear relationship between granule size fraction and 
tablet friability. In all formulations friability decreased 
with decreasing size of granules, but again there were 
higher percentage of friability were observed in tablets 
with less size fraction of granules such as formulation 
DGF (35/60; 500 – 250 µm). However, friability does not 
appear to be simply a function of crushing strength. For 
example, tablets containing intra-granular Kyron T-314 
tended to have lower crushing strength than those 
containing intra-granular Explotab and friability also 
tended to be lower. Tablet crushing strength, however, 
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does not necessarily reflect granule strength and this may 
explain the observed differences.[18]  
E - Tablet Disintegration 
The disintegration of tablets was checked as per the 
specification of disintegration for dispersible and 
Orodispersible tablets mentioned in British Pharmacopoeia 
were changes in disintegration time observed with change 
in type of disintegrant. So relationship between granule 
size and tablet disintegration and deaggregation is 
dependent on intra-granular disintegrant type. A graphical 
comparison of impact of particle size on tablet 
disintegration has shown in Graph- 1. 
Ac-Di-Sol caused rapid tablet disintegration as compare to 
other intra-granular disintegrants. In tablets containing 
intra-granular Ac-Di-Sol, the time taken for disintegration 
or deaggregation was largely unaffected by granule size 
fraction. But the longer disintegration times were observed 
with increasing granule size fraction in case of Kollidon-
CL and Kyron T-314. The higher disintegration of larger 
granules with Kollidon-CL, and Kyron T-314 was clearly 
observed due to slower bursting or deaggregation of 
granules during disintegration process. The larger granules 
fraction containing Kollidon-CL and Kyron T-314 was not 
able to pass the disintegrating sieves during disintegration 
resulted higher disintegration time.  
 
Table 6: Physical evaluation of tablets 
Evaluation Parameters/ 
Formulation Code 
A-1 
Explotab 
A-2 
Ac-di-sol 
A-3 
Kollidon-CL 
A-4 
Kyron T-314 
Appearance All  Off-white colored, round flat faced tablet 
% Wt. Variation  AGF 240.62± 4.20 241.34± 3.89 240.36± 4.25 239.25± 3.98 
BGF 241.20± 2.35 239.96± 2.30 238.25± 2.10 242.36± 1.96 
CGF 238.65± 2.20 237.96± 1.65 241.01± 1.80 238.85± 1.56 
DGF 243.29± 3.68 240.62± 3.95 242.12± 4.05 241.20± 3.80 
Avg. Hardness  
(in Newton) 
AGF 25.20± 2.50 28.00± 2.32 20.30± 3.00 22.40± 3.12 
BGF 28.67± 2.45 27.50± 2.20 24.50± 2.10 26.20± 1.80 
CGF 30.67± 2.20 32.00± 2.18 28.20± 2.18 25.00± 1.96 
DGF 32.67± 1.80 35.00± 1.80 30.33± 1.75 28.10± 1.26 
Avg. Thickness  
(in mm) 
AGF 3.19± 0.05 3.18± 0.06 3.20± 0.04 3.19± 0.06 
BGF 3.19± 0.04 3.19± 0.08 3.19± 0.10 3.20± 0.08 
CGF 3.18± 0.02 3.21± 0.04 3.20± 0.06 3.19± 0.06 
DGF 3.20± 0.05 3.19± 0.06 3.18± 0.06 3.20± 0.05 
Friability  
(in % w/w) 
AGF 0.58 0.65 0.56 0.62 
BGF 0.43 0.38 0.32 0.45 
CGF 0.42 0.30 0.29 0.32 
DGF 0.62 0.52 0.48 0.49 
Disintegration 
(in Seconds) 
AGF 25-30 20-25 100-150 120-180 
BGF 25-30 15-20 45-70 60-100 
CGF 20-25 18-20 30-40 50-80 
DGF 22-30 15-22 35-45 60-90 
Dispersion  
(in Seconds) 
AGF 58.27± 4.12 53.67± 3.53 156.6± 12.3 180± 15.53 
BGF 60.29± 5.13 50.67± 4.06 110.23± 16.3 150.3± 12.65 
CGF 48.63± 3.65 40.67± 1.53 89.32± 12.63 90.67± 15.36 
DGF 50.26± 2.36 38.02± 1.60 120.3± 15.30 100.32± 9.63 
 
There were very minor differences observed in 
disintegration time of smaller granules fraction, but the 
overall disintegration time does not show the significant 
changes. Poorer disintegrant efficiency means that size 
reduction of granules is more dependent on dissolution and 
therefore larger granules tend to exhibit longer 
disintegration times. 
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Disintegrant efficiency of Ac-Di-Sol is higher than 
Explotab and Kyron T-314 because whereas the latter two 
mainly cause disintegration by swelling, Ac-Di-Sol 
combines high swelling activity with wicking 
properties.[19] Wicking activity causes rapid penetration of 
water into the tablet and allows intra-granular Ac-Di-Sol to 
function effectively in a tablet without extra-granular 
disintegrant.[20, 21]
 
 
Graph 1: Effect of particle size fraction and various disintegrants on Disintegration Time of Tablets 
 
 
Graph 2: Effect of particle size fraction and various disintegrants on Dispersion Time of Tablets 
F - Tablet Dispersion and Fineness of dispersion 
The dispersion of the tablets provides the effective 
evaluation of the dispersion and deaggregation of granules 
in to fine particle which can be correlated for in-vivo 
release of formulations. A graphical comparison of impact 
of particle size on tablet dispersion and fineness of 
dispersion has shown in Graph - 2. 
In tablets compressed from all granule size fractions, the 
disintegration times remained the same but a significant 
changes was observed in dispersion time and fineness of 
dispersion. The dispersion time with Ac-di-sol and 
Explotab taking less time as compare to formulation 
containing Kyron T-314, and Kollidon-CL. Ac-Di-Sol 
caused rapid tablet dispersion, which is hardly affected by 
granules size fraction. Explotab functioned less efficiently 
than Ac-Di-Sol. Increasing granule Size and hardness 
adversely affected the dispersion of tablets containing 
intra-granular Explotab. Dispersion time increased with 
granule size and the fineness of dispersion also showing 
the same tendency.  
Generally, tablets made from the larger granules (1400-
1000µm) had a marbled surface, probably indicating 
higher inter-granular porosity due to the lack of fine 
particles to fill inter-granular spaces. These granules when 
tested for fineness of dispersion, shows retention of 
particle instead of rapid dispersion of granules (with Ac-
di-sol and Explotab). The same tendency also observed in 
case of smaller granule size fraction (500-250µm) with 
Kollidon-CL and Kyron T-314. This is due to overall 
reduction in tablet porosity because of fine material 
contained in the particular granules size fraction. 
Dispersion of tablets with granules size fraction between 
500 and 1000 µm (18/25; 1000 – 710 µm & 25/35; 710 – 
500 µm) showing excellent dispersion without any 
retention, the effect of disintegrants respect to final 
dispersion also not observed during dispersion study of 
tablets. Overall the tablets formulated with Ac di sol 
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showing better dispersion as compare to other disintegrants 
used in formulation.  
3.7.3 Analytical Evaluation of Tablets 
A - Assay of drug content in Tablets 
Assay of tablets for various formulations were summarized 
in Table - 7. For tablets containing Ac-Di-Sol, Explotab, 
Kollidon-CL, and Kyron T-314 the active drug content of 
the different granule fractions were similar. There were 
some variation observed in the assay of tablets with 
smaller granules size fractions, but practically the 
differences were small. So there were no significant effects 
of granules size fraction on active content of formulations. 
 
Table 7: Effect of Granule size fraction on Drug Content of Tablets 
Formulation Code Explotab Ac-di-sol Kollidon-CL Kyron T-314 
1 2 3 4 
AGF 99.50± 1.20 100.23± 1.25 101.20± 1.96 97.89± 1.96 
BGF 100.20± 1.35 98.63± 1.10 102.3± 1.20 100.96± 1.23 
CGF 101.23± 1.35 100.96± 1.25 97.25± 1.39 98.96± 1.96 
DGF 100.20± 1.05 100.35± 1.09 100.23± 1.95 100.23± 1.20 
 
B - In-vitro Drug Release Profile 
The release profile of various formulations was analyzed to 
evaluate the actual effect of disintegrants and granules size 
fraction and summarized in Graph - 3 to 6. The release 
profile of Ac-di-sol with higher granules size fractions 
(1400 – 1000, 1000 – 710 µm) showing similar but slow 
release profile in first 5 minutes time profile as compare to 
lower granules size fraction (710 – 500, 500 – 250 µm). 
There was no impact of size fraction at later stage in release 
profile of tablets. The basic properties of prompt release 
which is also basic requirement in formulation of rapid 
dispersible tablets can be easily achieved by using the 
optimized size of granules in development of rapid 
dispersible tablets.   
The release profile of Explotab with different granules size 
fraction shows significant changes with change in size of 
granules. The release profile of smaller granules fraction 
(500-250µm) is lower as compare to remaining granules 
size fractions. This may be due to high swelling of 
Explotab during deaggregation.
 [19]
 The increase 
compressibility and hardness also may be the reason for 
slower release of smaller granules size fraction. There was 
lowest release of active was observed in first five minutes 
with disintegrants such as Kollidon-CL, and Kyron T-314, 
the same phenomenon also observed during dispersion of 
tablets. The slow release was basically due to slower 
bursting effect of tablets at initial time points during 
dissolution study. The release profile at later stages was 
same but low as compare to Explotab and Ac di sol.    
On the basis of overall evaluation of release profile of 
tablets compressed with various size fractions of granules 
the formulation having Ac di sol and Explotab shows 
better release profile in first 5 minutes of release kinetics. 
The tablets compressed with granules size fraction 
between 500 and 1000 µm (1000 – 710, 710 – 500 µm) 
showing better release profile with all disintegrants used in 
formulation of rapid dispersible tablets.
 
 
 
Graph 3: Effect of Granule Size Fraction on In-vitro drug release profile of Tablets with Explotab as disintegrant 
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Graph 4: Effect of Granule Size Fraction on In-vitro drug release profile of Tablets with Ac di sol as disintegrant 
 
 
Graph 5: Effect of Granule Size Fraction on In-vitro drug release profile of Tablets with Kollidon-CL as disintegrant 
 
 
Graph 6: Effect of Granule Size Fraction on In-vitro drug release profile of Tablets with Kyron T-314 as disintegrant 
CONCLUSION: 
There was a clear effect of various disintegrants with 
different granules size fraction was observed on 
disintegration, dispersion and fineness of dispersion of 
rapid dispersible tablets. The rate and variability of 
dispersion was greatly influenced by intra-granular 
disintegrant type, which had a greater influence on 
dispersion and disintegration properties of tablets. Tablets 
containing Ac-Di-Sol disintegrated most rapidly with 
least variability. The dispersion characteristics of tablets 
containing intra-granular Explotab / Kyron T-314 are less 
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consistent. Used alone intra-granular, disintegrants 
efficiency can be summarized as: 
Ac-Di-Sol > Explotab > Kyron T-314 > Kollidon-CL 
The size of granules fraction also having a clear impact 
on dispersion and fineness of dispersion, the dispersion 
time was increasing with increasing the granules size 
fractions.  
On the basis of various physical and analytical 
investigations formulation containing Ac-di-sol 
(Formulation BGF-2 and CGF-2) was the most suitable 
candidate to use as disintegrants in this particular system. 
The choice of most suitable granules fractions was 
observed between 500 – 1000µm to formulate rapid 
dispersible tablets in this particular system. 
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